GlassScriptPhysician profile
Brett T Volpe
NPI 1235116948
$2,450.84
in general payments reported to CMS, 2019-2025
14 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $247 · 2021: $369 · 2023: $628 · 2024: $165 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $463.77 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $393.44 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $308.66 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $239.23 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $204.25 | 2024-2025 | Tezspire, Airsupra |
| Eisai INC. | $148.24 | 2020-2021 | |
| Harmony Biosciences LLC | $145.62 | 2023 | Wakix |
| Genzyme Corporation | $141.92 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $129.95 | 2024 | Dupixent |
| Sunovion Pharmaceuticals INC. | $124.43 | 2019 | |
| Mylan Specialty L.P. | $96.81 | 2019 | |
| 3b Medical, INC. | $24.21 | 2025 | Luna |
| Philips North America LLC | $18.05 | 2020 | |
| Itamar Medical INC | $12.26 | 2023-2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Volpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.